Skip to content
Original
mp.weixin.qq.com·· 1 day agoScore89

Lepu Biopharma Reports Significant OS Benefit for CMG901 Phase III and MRG007, MRG003 Data at ESMO 2026

In brief

Lepu Biopharma presented Phase III results for CMG901 (AZD0901) at ESMO 2026, showing significant overall survival benefit in CLDN18.2-positive advanced or metastatic gastroesophageal cancer. The company also reported preliminary clinical data for MRG007 (ARR-217) and MRG003 (vicistatumab, MRG003).

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#ADCs & conjugates#Immunotherapy#AstraZeneca
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.